USA Tumor-Infiltrating Lymphocyte (TIL) Therapy Market Size, Share, Trends and Forecasts 2032

Key Findings

• The USA Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is expanding rapidly as adoptive cell therapy gains traction in solid tumors.
• TIL therapy is emerging as a powerful personalized immunotherapy approach in oncology.
• Clinical progress in melanoma and other solid tumors is driving market momentum.
• Autologous TIL manufacturing platforms are becoming more standardized.
• Combination regimens with checkpoint inhibitors are increasing.
• Cell expansion and selection technologies are improving response rates.
• Investment and partnerships in cell therapy manufacturing are rising.
• High production complexity and treatment cost remain key barriers.

USA Tumor-Infiltrating Lymphocyte (TIL) Therapy Market Size and Forecast

The USA Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is projected to grow from USD 1.6 billion in 2025 to USD 7.5 billion by 2032, registering a CAGR of 24.7% during the forecast period. Growth is driven by increasing clinical validation of TIL therapy in solid tumors and rising adoption of personalized cell-based immunotherapies. Oncology centers are expanding capabilities for cell harvesting and expansion workflows.

Improvements in cell processing, selection, and conditioning regimens are enhancing outcomes. Regulatory progress and landmark approvals are accelerating commercialization pathways. The market is expected to expand strongly across USA through 2032.

Introduction

Tumor-infiltrating lymphocyte (TIL) therapy is an adoptive cell therapy approach in which immune T cells are extracted directly from a patient’s tumor, expanded and activated ex vivo, and then reinfused to attack cancer cells. These lymphocytes are naturally tumor-reactive, making them highly relevant therapeutic agents. In USA, TIL therapy is being developed primarily for solid tumors, including melanoma and other hard-to-treat cancers.

The therapy involves tumor resection, cell isolation, large-scale expansion, and lymphodepleting conditioning before infusion. TIL therapy represents one of the most personalized forms of cellular immunotherapy. It is increasingly positioned alongside CAR-T and TCR therapies in advanced oncology care.

Future Outlook

By 2032, TIL therapy in USA will benefit from more automated and closed manufacturing systems that reduce turnaround time and variability. Improved cell selection markers will enhance response predictability. Combination regimens with checkpoint inhibitors and cytokine support will expand. Decentralized and regional cell processing centers will improve access. Process standardization will lower failure rates and cost per treatment.

Overall, TIL therapy will move from niche specialized centers toward broader oncology network adoption.

USA Tumor-Infiltrating Lymphocyte (TIL) Therapy Market Trends

• Expansion of TIL Therapy Beyond Melanoma into Multiple Solid Tumors
  TIL therapy in USA is expanding beyond melanoma into additional solid tumor indications. Clinical programs are targeting cervical, lung, and gastrointestinal cancers. Broader tumor applicability is being validated through trials. Protocols are being adapted by tumor type. Research focus is widening across oncology segments. Indication expansion is a major trend.

• Standardization of TIL Manufacturing and Expansion Protocols
  Manufacturing workflows for TIL therapy are becoming more standardized. Cell isolation and expansion steps are being optimized. Closed and semi-automated systems are increasing. Process reproducibility is improving across sites. Standard protocols reduce variability risk. Manufacturing standardization is accelerating.

• Integration with Checkpoint Inhibitors and Immune Modulators
  TIL therapies are increasingly combined with checkpoint inhibitors. Checkpoint blockade enhances infused cell activity. Combination regimens improve durability of response. Trial designs frequently include combo arms. Immune modulation support is expanding. Combination strategies are trending.

• Advances in Cell Selection and Phenotyping Technologies
  New tools are improving selection of high-quality TIL populations. Phenotyping identifies more active cell subsets. Functional screening improves potency. Selection methods raise response probability. Biomarker-guided selection is emerging. Cell quality optimization is a key trend.

• Development of Automated and Closed Cell Processing Systems
  Automated cell processing platforms are being introduced in USA. Closed systems reduce contamination risk. Manual handling steps are reduced. Scalability improves with automation. Labor requirements decline. Automation is reshaping operations.

Market Growth Drivers

• Strong Clinical Responses in Refractory Solid Tumors
  TIL therapy has shown strong responses in refractory cancers. Patients with limited options benefit most. Durable responses are observed in subsets. Clinical momentum is increasing. Physician interest is rising in USA. Clinical success drives growth.

• Rising Demand for Personalized Cell-Based Immunotherapies
  Personalized immunotherapy demand is increasing. TIL therapy is inherently patient-specific. Tumor-reactive cells are directly used. Precision immune targeting is achieved. Personalized oncology is expanding. Demand supports adoption.

• Advances in Cell Culture and Expansion Technologies
  Cell expansion methods are improving steadily. Culture systems are more efficient. Growth media and cytokine protocols are optimized. Expansion timelines are shortening. Yield reliability is improving. Technology progress fuels the market.

• Growing Investment in Cell Therapy Infrastructure
  Investment in cell therapy facilities is rising. Specialized manufacturing centers are expanding in USA. Infrastructure supports TIL scale-up. Platform investments reduce unit cost over time. Capacity growth enables commercialization. Infrastructure funding is a driver.

• Supportive Regulatory Pathways for Advanced Cell Therapies
  Advanced therapy regulatory pathways are evolving. Accelerated programs are available. Breakthrough and priority designations support timelines. Engagement with regulators is improving. Framework clarity is increasing. Regulatory support drives growth.

Challenges in the Market

• Complex and Lengthy Manufacturing Workflow
  TIL therapy manufacturing is multi-step and time intensive. Tumor extraction is required first. Cell expansion takes weeks. Coordination is complex in USA. Delays can affect eligibility. Workflow complexity is a major barrier.

• High Treatment Cost and Resource Requirements
  TIL therapy is resource intensive. Specialized facilities are required. Skilled staff are needed. Per-patient cost is high. Reimbursement models are evolving. Cost pressure is significant.

• Patient Eligibility and Tumor Tissue Requirements
  Not all patients are eligible for TIL therapy. Adequate tumor tissue is required. Surgical access may be limited. Cell yield can vary. Some tumors produce weak TIL populations. Eligibility limits scale.

• Safety Risks from Conditioning Regimens
  Lymphodepleting regimens are often required. These can cause significant toxicity. Hospital monitoring is needed. Supportive care burden is high. Risk management is critical. Safety complexity is a constraint.

• Logistics and Chain-of-Identity Management
  Autologous therapies require strict identity tracking. Chain-of-custody must be maintained. Logistics errors have high impact. Tracking systems must be robust in USA. Coordination across sites is complex. Logistics risk is a challenge.

USA Tumor-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation

By Therapy Type

• Autologous TIL Therapy

• Enhanced/Selected TIL Therapy

By Indication

• Melanoma

• Cervical Cancer

• Lung Cancer

• Gastrointestinal Cancers

• Others

By Therapy Mode

• Monotherapy

• Combination Therapy

By End-User

• Specialized Cancer Centers

• Hospitals

• Academic Medical Centers

Leading Key Players

• Iovance Biotherapeutics

• Instil Bio

• Turnstone Biologics

• Achilles Therapeutics

• Adaptimmune Therapeutics

• Bristol Myers Squibb

• Roche

• Merck & Co., Inc.

Recent Developments

• Iovance Biotherapeutics advanced commercial-scale TIL therapy manufacturing and late-stage melanoma programs.

• Instil Bio expanded next-generation TIL platform development for solid tumors.

• Turnstone Biologics progressed selected TIL therapy candidates with enhanced potency profiles.

• Achilles Therapeutics advanced precision T-cell and tumor-reactive cell therapy platforms.

• Bristol Myers Squibb expanded combination immunotherapy collaborations including cell-based approaches.

This Market Report Will Answer the Following Questions

1. What is the projected market size and growth rate of the USA TIL Therapy Market by 2032?

2. Which tumor indications are driving TIL therapy adoption in USA?

3. How are automation and cell selection technologies improving outcomes?

4. What challenges affect manufacturing, cost, and patient eligibility?

5. Who are the key players driving innovation in TIL therapy?